SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions, Inc., one of the leading providers of advanced technologies and outsourced services to the global pharmaceutical, biotechnology and consumer health industry, announced its financial results for its third fiscal quarter ended March 31, 2008. Catalent recognized net revenue of $453.3 million and EBITDA from continuing operations of $56.5 million for the three months then ended, after giving effect to the Acquisition and related purchase method of accounting adjustments. EBITDA and Adjusted EBITDA as detailed in the attached schedules for the twelve months ended March 31, 2008 were $51.4 million and $342.7 million, respectively. EBITDA and Adjusted EBITDA are defined below under “Non-GAAP Financial Matters.”
